Literature DB >> 11096698

Idiopathic Intracranial Hypertension.

.   

Abstract

A thorough assessment of vision with special attention to formal visual field testing is the cornerstone to decision making in idiopathic intracranial hypertension. After the diagnosis of idiopathic intracranial hypertension has been established, vision should be thoroughly assessed. If there is no visual loss, the patient can be followed carefully. In patients with symptoms and only a few signs (eg, mild blind-spot enlargement), acetazolamide, 1 to 2 g, or another diuretic should be initiated. In patients with progressive visual loss in whom maximal diuretic therapy fails and in those who on initial evaluation have significant recent visual loss that does not respond to maximal diuretic therapy, optic nerve sheath decompression or lumbar peritoneal shunting should be carried out. With all treatments, weight loss should be encouraged. All patients should be evaluated regularly with visual field testing.

Entities:  

Year:  1999        PMID: 11096698     DOI: 10.1007/s11940-999-0035-3

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  35 in total

1.  Treatment of benign intracranial hypertension by dehydrating agents with particular reference to the measurement of the blind spot area as a means of recording improvement.

Authors:  A Jefferson; J Clark
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-07       Impact factor: 10.154

2.  Optic nerve sheath fenestration for pseudotumor cerebri.

Authors:  K Y Goh; N J Schatz; J S Glaser
Journal:  J Neuroophthalmol       Date:  1997-06       Impact factor: 3.042

3.  The 1982 Silversides lecture. Problems in the diagnosis and treatment of pseudotumor cerebri.

Authors:  J J Corbett
Journal:  Can J Neurol Sci       Date:  1983-11       Impact factor: 2.104

4.  The production of cerebrospinal fluid in man and its modification by acetazolamide.

Authors:  R C Rubin; E S Henderson; A K Ommaya; M D Walker; D P Rall
Journal:  J Neurosurg       Date:  1966-10       Impact factor: 5.115

5.  [Hyperbaric oxygen therapy in the treatment of benign intracranial hypertension. Follow-up of a preliminary study].

Authors:  C Luongo; R Mignini; C Vicario; A Sammartino
Journal:  Minerva Anestesiol       Date:  1992-04       Impact factor: 3.051

6.  Optic nerve decompression surgery improves visual function in patients with pseudotumor cerebri.

Authors:  S E Kelman; R Heaps; A Wolf; M J Elman
Journal:  Neurosurgery       Date:  1992-03       Impact factor: 4.654

Review 7.  [Complications of lumboperitoneal shunts. A retrospective study of a series of 195 patients (214 procedures)].

Authors:  R Duthel; C Nuti; M J Motuo-Fotso; P Beauchesne; J Brunon
Journal:  Neurochirurgie       Date:  1996       Impact factor: 1.553

8.  Results of optic nerve sheath fenestration for pseudotumor cerebri. The lateral orbitotomy approach.

Authors:  J J Corbett; J A Nerad; D T Tse; R L Anderson
Journal:  Arch Ophthalmol       Date:  1988-10

9.  The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana.

Authors:  F J Durcan; J J Corbett; M Wall
Journal:  Arch Neurol       Date:  1988-08

10.  Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study.

Authors:  V Giuseffi; M Wall; P Z Siegel; P B Rojas
Journal:  Neurology       Date:  1991-02       Impact factor: 9.910

View more
  2 in total

Review 1.  Idiopathic intracranial hypertension headache.

Authors:  Kathleen B Digre
Journal:  Curr Pain Headache Rep       Date:  2002-06

2.  Clinical and Prognostic Significance of Cerebrospinal Fluid Opening and Closing Pressures in Pediatric Pseudotumor Cerebri Syndrome.

Authors:  Shannon J Beres; Claire A Sheldon; Chantal J Boisvert; Christina L Szperka; Grace L Paley; Evanette K Burrows; Marianne R Chilutti; Geraldine W Liu; Shana E McCormack; Grant T Liu
Journal:  Pediatr Neurol       Date:  2018-03-30       Impact factor: 3.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.